ELISPOT in Cancer Research

ELISPOT and cancerDevelopment of cervical cancer and hepatocellular carcinoma is strongly associated with high-risk human papillomavirus (HPV) and hepatitis B virus (HBV) infection, respectively. Researchers try to bring these forms of cancer to a halt by looking for specific and selective tumor antigens (often of viral origin) to apply in tumor-specific cancer vaccines. For this work, researchers need to monitor the kinetics of vaccine-induced T cell immunity and study the ability of antigens to induce specific cytotoxic T lymphocyte activity in vitro. For this purpose, the ELISPOT assay is an ideal tool to detect peptide-specific activated functional CD8 (+) cytotoxic T lymphocytes. By using a pool of peripheral blood mononuclear cells, the peptide of interest may be compared to control peptides, for its ability to induce cytokine release by single T cells. The researcher can use the number of spots in the ELISPOT to quantify responder T cell frequencies and evaluate the immunogenicity of these possible vaccines.

Back to ELISPOT in other research areas

Examples of studies using our ELISPOT assays:

Click on the authors for the abstract of the below mentioned acticles or find them in our Reference Database.

Bian T., Wang Y., Lu Z., Ye Z., Zhao L., Ren J., Zhang H., Ruan L. and  Tian H.
Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice.
Mol. Cancer Ther. 7:1329-35 (2008).
U-CyTech products used in this study:
Mouse IFN-γ ELISPOT kit
Chiriva-Internati M., Yu Y., Mirandola L., Jenkins M.R., Chapman C., Cannon M., Cobos E. and Kast W.M.
Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.
PLoS One 5:e10471 (2010).
U-CyTech products used in this study:
Mouse IFN-γ ELISPOT kit
Mouse TNF-α ELISPOT kit
Gholamin M., Moaven O., Farshchian M., Mahmoudi M., Sankian M., Memar B., Forghani,M.N., Malekzadeh R., Rajabi-Mashhadi M.T. and Abbaszadegan M.R.
Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design.
BMC Cancer 10:261 (2010).
U-CyTech products used in this study:
Human IFN-γ ELISPOT kit

Griffioen M., Borghi M., Schrier P.I., Osanto S. and Schadendorf D.
Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunol Immunother 53:715-22 (2004).
U-CyTech products used in this study:
Human IL-13 ELISPOT kit

Grossardt C., Engeland C.E., Bossow S., Halama N., Zaoui K., Leber M.F., Springfeld C., Jaeger D., von Kalle C. and Ungerechts G.
Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Hum. Gene Ther. 24:644-54 (2013).
U-CyTech products used in this study:
Mouse IFN-γ ELISPOT kit
Li J., Zeng X.H., Mo H.Y., Rolen U., Gao Y.F., Zhang X.S., Chen Q.Y., Zhang L., Zeng M.S., Li M.Z., Huang W.L., Wang X.N., Zeng Y.X. and Masucci M.G.
Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy.
PLoS One 2:e1122 (2007). 
U-CyTech products used in this study:
Human IFN-γ ELISPOT kit

Shang X.Y., Chen H.S., Zhang H.G., Pang X.W., Qiao H., Peng J.R., Qin L.L., Fei R., Mei M.H., Leng X.S., Gnjatic S., Ritter G., Simpson A.J., Old L.J. and Chen W.F.
The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin. Cancer Res. 10:6946-55 (2004).
U-CyTech products used in this study:
Human Granzyme B ELISPOT antibody pair
Slager, E. H., Borghi, M., van der Minne, C. E., Aarnoudse, C. A., Havenga, M. J., Schrier, P. I., Osanto, S., and Griffioen, M.
CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame.
J. Immunol. 170:1490-7 (2003).
U-CyTech products used in this study:
Monkey IL-13 ELISPOT kit
Monkey species: Macaca mulatta